MD Anderson reported new data on why off-the-shelf CAR T therapies succeed for some patients but fail for others. The study found that pre-existing immune rejection and intrinsic donor CAR T cell fitness were key determinants of outcomes, reframing patient selection and manufacturing readouts around immune competence and cellular robustness. In a separate update, UChicago Medicine launched an investigator-initiated first-of-its-kind trial of an on-site manufactured T-cell receptor therapy targeting NY-ESO-1 and engineered to resist TGF-beta suppression in advanced solid tumors. The trial reflects ongoing efforts to address immunosuppressive tumor microenvironments for solid-tumor cell therapies. Both updates emphasize practical hurdles—immune rejection, persistence, and microenvironment suppression—that now shape next moves in next-generation cellular immunotherapy.